Researchers Report Thymosin Beta 4 Significantly Reduces Damage from Traumatic Brain Injury & Improves Brain Function in Expe...
24 Maio 2010 - 9:30AM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN)
announced today that in a preclinical research paper published in
the May 2010 issue of the Journal of
Neurosurgery, (online ahead of publication), scientists
found that the systemic administration of thymosin beta 4, or Tβ4,
significantly reduced brain tissue damage and improved brain
function in rats with traumatic brain injury, or TBI. In the study,
10 rats were injected with Tβ4 one day following the inducement of
TBI and four times thereafter over a 12-day period, while 9 rats
were injected with a placebo or saline solution. In the group of
rats treated with Tβ4, researchers observed reduced cell loss in
the hippocampus, a part of the brain that plays an important role
in long-term memory, as compared to the placebo group. The rats
treated with Tβ4 also experienced growth of new blood vessels and
neurons in the injured cerebral cortex, growth of brain cells known
as oligodendrocytes in the CA3 field of the hippocampus, and
recovery of sensory and motor functions as well as spatial
learning. The researchers noted that the data for the first time
demonstrate that delayed administration of Tβ4 significantly
improves histological and functional outcomes in rats with TBI,
indicating that Tβ4 has considerable therapeutic potential for
patients with TBI.
“We believe these results are very encouraging. The fact that
Tβ4 was administered beginning one day following injury and was
still able to improve outcomes is significant,” added Dr. Allan L.
Goldstein, professor of biochemistry and molecular biology at the
George Washington University Medical School, and chairman of the
board of directors and chief scientific advisor for RegeneRx. “We
have now seen compelling data using Tβ4 in three different animal
models — an EAE mouse model for multiple sclerosis, a rat model for
embolic stroke, and this new study in traumatic brain injury — that
have each demonstrated Tβ4’s ability to promote angiogenesis,
regenerate neuronal tissue, and improve functional outcome. These
data are also consistent with previously published studies showing
regeneration of heart tissue after ischemic injuries to the
myocardium.”
About RegeneRx
Biopharmaceuticals, Inc.
RegeneRx is focused on the development of a novel therapeutic
peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection,
repair and regeneration. Currently, RegeneRx has formulated three
product candidates in clinical development: RGN-352, an injectable
formulation for systemic delivery to treat cardiovascular diseases,
central nervous system diseases, and other medical indications that
require administration by injection, that has completed a Phase 1
clinical trial; RGN-259, a sterile, preservative-free topical eye
drop for ophthalmic indications that is currently being supported
in compassionate use studies; and RGN-137, a topically applied gel
for chronic dermal wounds and reduction of scar tissue that is
currently in a Phase 2 clinical trial for the treatment of
epidermolysis bullosa. RegeneRx is initially targeting RGN-352 for
the treatment of patients who have suffered an acute myocardial
infarction, or heart attack, although recent animal research
suggests that this formulation may also benefit patients with
multiple sclerosis and stroke. RegeneRx has a fourth product
candidate, RGN-457, which is an inhaled formulation targeting
cystic fibrosis and other pulmonary diseases, in pre-clinical
development. These product candidates are based on Tβ4, a synthetic
copy of a 43-amino acid, naturally-occurring peptide that is the
subject of an exclusive worldwide license from the National
Institutes of Health. In addition to the four pharmaceutical
product candidates described above, RegeneRx is pursuing the
commercial development of peptide fragments of Tβ4 for potential
cosmeceutical use. RegeneRx holds over 60 worldwide patents and
patent applications related to its product candidates.
Forward-Looking
Statements
Any statements in this press release that are not historical
facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve risks and uncertainties that
could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. You are urged to consider
statements that include the words “project,” “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,”
“would,” “could,” “will,” ”may,” “potential” or the negative of
those words or other similar expressions words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risks and uncertainties
inherent in our business, including, without limitation the risk
that our product candidates do not demonstrate safety and/or
efficacy in future clinical trials; risks related to our ability to
obtain financing to support our operations on commercially
reasonable terms; the progress, timing or success of our clinical
trials; difficulties or delays in development, testing, obtaining
regulatory approval for producing and marketing our product
candidates; regulatory developments; the size and growth potential
of the markets for our product candidates and our ability to serve
those markets; the scope and validity of patent protection for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and other risks described in the Company’s
filings with the Securities and Exchange Commission (“SEC”),
including those identified in the “Risk Factors” sections of the
annual report on Form 10-K for the year ended December 31, 2009,
filed with the SEC on March 31, 2009, and the quarterly report on
Form 10-Q for the quarter ended March 31, 2010, filed with the SEC
on May 17, 2010, as well as other filings it makes with the SEC.
Any forward-looking statements in this press release represent the
Company’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
The Company anticipates that subsequent events and developments may
cause its views to change, and the Company specifically disclaims
any obligation to update this information, as a result of future
events or otherwise, except as required by applicable law.
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024